Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1699-1715

  Yin, Qi ^a   Shen, Jianan ^a   Zhang, Zhiwen ^a   Yu, Haijun ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Chemotherapy; Drug delivery; Multidrug resistance; Responsive; Stimuli; Tumor

Indexed keywords

CHEMOTHERAPEUTIC AGENTS; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; MULTIDRUG RESISTANCE; RATE-LIMITING STEPS; RESPONSIVE; STIMULI; STIMULI-RESPONSIVE DRUG DELIVERIES;

CHEMOTHERAPY; ONCOLOGY; TUMORS;

DRUG DELIVERY;

CAMPTOTHECIN; COPOLYMER; CURCUMIN; DOXORUBICIN; IDARUBICIN; PACLITAXEL; PENICILLAMINE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMICAL BOND; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYDROPHOBICITY; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PH; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SOLID TUMOR; STIMULUS RESPONSE; TUMOR XENOGRAFT; UTERUS SARCOMA;

CHEMOTHERAPY; DRUG DELIVERY; MULTIDRUG RESISTANCE; RESPONSIVE; STIMULI; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; LIGHT; MAGNETIC FIELDS; NEOPLASMS; OXIDATION-REDUCTION; ULTRASONICS;

EID: 84888206128     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.04.011     Document Type: Review

References (232)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Bouwman P., Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 2012, 12:587-598.
3. Moroney J., Fu S., Moulder S., Falchook G., Helgason T., Levenback C., Hong D., Naing A., Wheler J., Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mtor/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin. Cancer Res. 2012, 18:5796-5805.
4. Liang X.J., Chen C., Zhao Y., Wang P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol. Biol. 2010, 596:467-488.
5. Bock C., Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat. Rev. Cancer 2012, 12:494-501.
6. Huang I.P., Sun S.P., Cheng S.H., Lee C.H., Wu C.Y., Yang C.S., Lo L.W., Lai Y.K. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol. Cancer Ther. 2011, 10:761-769.
7. Wilting R.H., Dannenberg J.-H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updat. 2012, 15:21-38.
8. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
9. Baguley B. Multidrug resistance in cancer. Multi-drug Resistance in Cancer 2010, 1-14. Humana Press. J. Zhou (Ed.).
10. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14:150-163.
11. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G., Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10737-10742.
12. Gillet J.-P., Gottesman M. Mechanisms of multidrug resistance in cancer. Multi-drug Resistance in Cancer 2010, 47-76. Humana Press. J. Zhou (Ed.).
13. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30:679-692.
14. Fan S., Niu Y., Tan N., Wu Z., Wang Y., You H., Ke R., Song J., Shen Q., Wang W., Yao G., Shu H., Lin H., Yao M., Zhang Z., Gu J., Qin W. Lass2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of v-ATPase proton pump. Oncogene 2012, 10.1038/onc.2012.183.
15. 2+ mediates granule motion and exocytosis. Cell Calcium 2012, 51:338-341.
16. Chen Y., Arriaga E.A. Individual acidic organelle pH measurements by capillary electrophoresis. Anal. Chem. 2006, 78:820-826.
17. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., Mumper R.J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69:3918-3926.
18. Bansal T., Akhtar N., Jaggi M., Khar R.K., Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today 2009, 14:1067-1074.
19. Yang L., Meng L., Zhang X., Chen Y., Zhu G., Liu H., Xiong X., Sefah K., Tan W. Engineering polymeric aptamers for selective cytotoxicity. J. Am. Chem. Soc. 2011, 133:13380-13386.
20. Oh J.K., Lee D.I., Park J.M. Biopolymer-based microgels/nanogels for drug delivery applications. Prog. Polym. Sci. 2009, 34:1261-1282.
21. Li B., Xu H., Li Z., Yao M., Xie M., Shen H., Shen S., Wang X., Jin Y. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int. J. Nanomedicine 2012, 7:187-197.
22. Wang X.X., Li Y.B., Yao H.J., Ju R.J., Zhang Y., Li R.J., Yu Y., Zhang L., Lu W.L. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011, 32:5673-5687.
23. Gao Y., Chen Y., Ji X., He X., Yin Q., Zhang Z., Shi J., Li Y. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano 2011, 5:9788-9798.
24. Wang F., Zhang D., Zhang Q., Chen Y., Zheng D., Hao L., Duan C., Jia L., Liu G., Liu Y. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 2011, 32:9444-9456.
25. Wang X., Li J., Wang Y., Koenig L., Gjyrezi A., Giannakakou P., Shin E., Tighiouart M., Chen Z., Nie S., Shin D. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5:6184-6194.
26. Perche F., Patel N., Torchilin V. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J. Control. Release 2012, 164:95-102.
27. Xue H., Wong H. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011, 5:7034-7047.
28. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2012, 24:24-36.
29. Kinsella J.M., Jimenez R.E., Karmali P.P., Rush A.M., Kotamraju V.R., Gianneschi N.C., Ruoslahti E., Stupack D., Sailor M.J. X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew. Chem. Int. Ed. Engl. 2011, 50:12308-12311.
30. Botella P., Abasolo I., Fernandez Y., Muniesa C., Miranda S., Quesada M., Ruiz J., Schwartz S., Corma A. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. J. Control. Release 2011, 156:246-257.
31. Peng X.-H., Wang Y., Huang D., Wang Y., Shin H.J., Chen Z., Spewak M.B., Mao H., Wang X., Wang Y., Chen Z., Nie S., Shin D.M. Targeted delivery of cisplatin to lung cancer using scfVEGFR-heparin-cisplatin nanoparticles. ACS Nano 2011, 5:9480-9493.
32. Park K.M., Lee D.W., Sarkar B., Jung H., Kim J., Ko Y.H., Lee K.E., Jeon H., Kim K. Reduction-sensitive, robust vesicles with a non-covalently modifiable surface as a multifunctional drug-delivery platform. Small 2010, 6:1430-1441.
33. Zheng C., Xu J., Yao X., Xu J., Qiu L. Polyphosphazene nanoparticles for cytoplasmic release of doxorubicin with improved cytotoxicity against DOX-resistant tumor cells. J. Colloid Interface Sci. 2011, 355:374-382.
34. Soldati T., Schliwa M. Powering membrane traffic in endocytosis and recycling. Nat. Rev. Mol. Cell Biol. 2006, 7:897-908.
35. Chithrani B.D., Chan W.C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 2007, 7:1542-1550.
36. Chu Z., Huang Y., Tao Q., Li Q. Cellular uptake, evolution, and excretion of silica nanoparticles in human cells. Nanoscale 2011, 3:3291-3299.
37. Qiu L., Zheng C., Zhao Q. Mechanisms of drug resistance reversal in DOX-resistant MCF-7 cells by pH-responsive amphiphilic polyphosphazene containing diisopropylamino side groups. Mol. Pharm. 2012, 9:1109-1117.
38. Ghosh P., Yang X., Arvizo R., Zhu Z.J., Agasti S.S., Mo Z., Rotello V.M. Intracellular delivery of a membrane-impermeable enzyme in active form using functionalized gold nanoparticles. J. Am. Chem. Soc. 2010, 132:2642-2645.
39. Salomone F., Cardarelli F., Di Luca M., Boccardi C., Nifosì R., Bardi G., Di Bari L., Serresi M., Beltram F. A novel chimeric cell-penetrating peptide with membrane-disruptive properties for efficient endosomal escape. J. Control. Release 2012, 163:293-303.
40. Febvay S.b., Marini D.M., Belcher A.M., Clapham D.E. Targeted cytosolic delivery of cell-impermeable compounds by nanoparticle-mediated, light-triggered endosome disruption. Nano Lett. 2010, 10:2211-2219.
41. Broaders K.E., Pastine S.J., Grandhe S., Frechet J.M. Acid-degradable solid-walled microcapsules for pH-responsive burst-release drug delivery. Chem. Commun. (Camb.) 2011, 47:665-667.
42. Meng F., Zhong Z., Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10:197-209.
43. Wang Y., Guo M., Lu Y., Ding L., Ron W., Liu Y., Song F., Yu S. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology 2012, 23:495103.
44. Wang J., Sun J., Chen Q., Gao Y., Li L., Li H., Leng D., Wang Y., Sun Y., Jing Y., Wang S., He Z. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 2012, 33:6877-6888.
45. Abbasi M., Lavasanifar A., Uludǎ H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med. Res. Rev. 2013, 33:33-53.
46. Fan L., Li F., Zhang H., Wang Y., Cheng C., Li X., Gu C.H., Yang Q., Wu H., Zhang S. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 2010, 31:5634-5642.
47. Li Y., Gao G.H., Lee D.S. Stimulus-sensitive polymeric nanoparticles and their applications as drug and gene carriers. Adv. Healthc. Mater. 2012, 10.1002/adhm.201200313.
48. Stuart M., Huck W., Genzer J., Müller M., Ober C., Stamm M., Sukhorukov G., Szleifer I., Tsukruk V., Urban M., Winnik F., Zauscher S., Luzinov I., Minko S. Emerging applications of stimuli-responsive polymer materials. Nat. Mater. 2010, 9:101-113.
49. Chen C., Geng J., Pu F., Yang X., Ren J., Qu X. Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery. Angew. Chem. Int. Ed. Engl. 2011, 50:882-886.
50. Yan Y., Johnston A., Dodds S., Kamphuis M., Ferguson C., Parton R., Nice E., Heath J., Caruso F. Uptake and intracellular fate of disulfide-bonded polymer hydrogel capsules for doxorubicin delivery to colorectal cancer cells. ACS Nano 2010, 4:2928-2936.
51. Wu W., Shen J., Gai Z., Hong K., Banerjee P., Zhou S. Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery. Biomaterials 2011, 32:9876-9887.
52. Liang L., Lin S.W., Dai W., Lu J.K., Yang T.Y., Xiang Y., Zhang Y., Li R.T., Zhang Q. Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J. Control. Release 2012, 160:618-629.
53. Namiki Y., Fuchigami T., Tada N., Kawamura R., Matsunuma S., Kitamoto Y., Nakagawa M. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc. Chem. Res. 2011, 44:1080-1093.
54. Sun L., Yang Y., Dong C.M., Wei Y. Two-photon-sensitive and sugar-targeted nanocarriers from degradable and dendritic amphiphiles. Small 2011, 7:401-406.
55. Sun G., Guan Z. Synthesis and investigation of core-shell dendritic nanoparticles with tunable thermosensitivity. Macromolecules 2010, 43:9668-9673.
56. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 2012, 64:866-884.
57. Zhang Q., Ko N.R., Oh J.K. Recent advances in stimuli-responsive degradable block copolymer micelles: synthesis and controlled drug delivery applications. Chem. Commun. (Camb.) 2012, 48:7542-7552.
58. Cabane E., Zhang X., Langowska K., Palivan C.G., Meier W. Stimuli-responsive polymers and their applications in nanomedicine. Biointerphases 2012, 7:9.
59. Muthu M.S., Rajesh C.V., Mishra A., Singh S. Stimulus-responsive targeted nanomicelles for effective cancer therapy. Nanomedicine (Lond.) 2009, 4:657-667.
60. Shim M.S., Kwon Y.J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv. Drug Deliv. Rev. 2012, 64:1046-1059.
61. Löwik D., Leunissen E., van den Heuvel M., Hansen M., van Hest J. Stimulus responsive peptide based materials. Chem. Soc. Rev. 2010, 39:3394-3412.
62. Du J.Z., Sun T.M., Song W.J., Wu J., Wang J. A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew. Chem. Int. Ed. Engl. 2010, 49:3621-3626.
63. Wang X., Chen C., Huo D., Qian H., Ding Y., Hu Y., Jiang X. Synthesis of β-cyclodextrin modified chitosan-poly(acrylic acid) nanoparticles and use as drug carriers. Carbohydr. Polym. 2012, 90:361-369.
64. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 2011, 11:59-67.
65. Modi S., S.M.G., Goswami D., Gupta G.D., Mayor S., Krishnan Y. A DNA nanomachine that maps spatial and temporal pH changes inside living cells. Nat. Nanotechnol. 2009, 4:325-330.
66. He Y., Bi Y., Hua Y., Liu D., Wen S., Wang Q., Li M., Zhu J., Lin T., He D., Li X., Wang Z., Wei G. Ultrasound microbubble-mediated delivery of the siRNAs targeting mdr1 reduces drug resistance of yolk sac carcinoma l2 cells. J. Exp. Clin. Cancer Res. 2011, 30:104.
67. Sun Y.L., Patel A., Kumar P., Chen Z.S. Role of ABC transporters in cancer chemotherapy. Chin. J. Cancer 2012, 31:51-57.
68. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10:147-156.
69. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., Dahlin A., Evers R., Fischer V., Hillgren K.M., Hoffmaster K.A., Ishikawa T., Keppler D., Kim R.B., Lee C.A., Niemi M., Polli J.W., Sugiyama Y., Swaan P.W., Ware J.A., Wright S.H., Yee S.W., Zamek-Gliszczynski M.J., Zhang L. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9:215-236.
70. She W., Luo K., Zhang C., Wang G., Geng Y., Li L., He B., Gu Z. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. Biomaterials 2013, 34:1613-1623.
71. Fan J., Fang G., Zeng F., Wang X., Wu S. Water-dispersible fullerene aggregates as a targeted anticancer prodrug with both chemo- and photodynamic therapeutic actions. Small 2012, 10.1002/smll.201201456.
72. Xing L., Zheng H., Cao Y., Che S. Coordination polymer coated mesoporous silica nanoparticles for pH-responsive drug release. Adv. Mater. 2012, 24:6433-6437.
73. Tang R., Ji W., Panus D., Palumbo R.N., Wang C. Block copolymer micelles with acid-labile ortho ester side-chains: synthesis, characterization, and enhanced drug delivery to human glioma cells. J. Control. Release 2011, 151:18-27.
74. Wu X.L., Kim J.H., Koo H., Bae S.M., Shin H., Kim M.S., Lee B.H., Park R.W., Kim I.S., Choi K., Kwon I.C., Kim K., Lee D.S. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug. Chem. 2010, 21:208-213.
75. Wen H., Guo J., Chang B., Yang W. pH-responsive composite microspheres based on magnetic mesoporous silica nanoparticle for drug delivery. Eur. J. Pharm. Biopharm. 2012, 10.1016/j.ejpb.2012.11.019.
76. Fan J., Zeng F., Wu S., Wang X. Polymer micelle with pH-triggered hydrophobic-hydrophilic transition and de-cross-linking process in the core and its application for targeted anticancer drug delivery. Biomacromolecules 2012, 13:4126-4137.
77. Yu H., Zou Y., Wang Y., Huang X., Huang G., Sumer B.D., Boothman D.A., Gao J. Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. ACS Nano 2011, 5:9246-9255.
78. Wu Y., Chen W., Meng F., Wang Z., Cheng R., Deng C., Liu H., Zhong Z. Core-crosslinked pH-sensitive degradable micelles: a promising approach to resolve the extracellular stability versus intracellular drug release dilemma. J. Control. Release 2012, 164:338-345.
79. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., Zhang Y., Barnhart T.E., Cai W., Gong S. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
80. Kaminskas L.M., McLeod V.M., Kelly B.D., Cullinane C., Sberna G., Williamson M., Boyd B.J., Owen D.J., Porter C.J. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol. Pharm. 2012, 9:422-432.
81. Cai X., Dong C., Dong H., Wang G., Pauletti G.M., Pan X., Wen H., Mehl I., Li Y., Shi D. Effective gene delivery using stimulus-responsive catiomer designed with redox-sensitive disulfide and acid-labile imine linkers. Biomacromolecules 2012, 13:1024-1034.
82. Ke C.J., Lin Y.J., Hu Y.C., Chiang W.L., Chen K.J., Yang W.C., Liu H.L., Fu C.C., Sung H.W. Multidrug release based on microneedle arrays filled with pH-responsive PLGA hollow microspheres. Biomaterials 2012, 33:5156-5165.
83. 2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chem. Commun. (Camb.) 2012, 48:4869-4871.
84. Ke C.J., Chiang W.L., Liao Z.X., Chen H.L., Lai P.S., Sun J.S., Sung H.W. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials 2012, 34:1-10.
85. MacEwan S.R., Callahan D.J., Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond.) 2010, 5:793-806.
86. Zou J., Zhang S., Shrestha R., Seetho K., Donley C.L., Wooley K.L. pH-triggered reversible morphological inversion of orthogonally-addressable poly(3-acrylamidophenylboronic acid)-block-poly(acrylamidoethylamine) micelles and their shell crosslinked nanoparticles. J. Polym. Sci. A Polym. Chem. 2012, 3:3146-3156.
87. Lee B.R., Baik H.J., Oh N.M., Lee E.S. Intelligent polymeric nanocarriers responding to physical or biological signals: a new paradigm of cytosolic drug delivery for tumor treatment. Polymers 2010, 2:86-101.
88. Lee E.S., Shin H.J., Na K., Bae Y.H. Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization. J. Control. Release 2003, 90:363-374.
89. Lee E.S., Na K., Bae Y.H. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 2003, 91:103-113.
90. Kim D., Lee E.S., Oh K.T., Gao Z.G., Bae Y.H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008, 4:2043-2050.
91. Kim D., Gao Z.G., Lee E.S., Bae Y.H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol. Pharm. 2009, 6:1353-1362.
92. Fan Y., Li C., Cao H., Li F., Chen D. The intranuclear release of a potential anticancer drug from small nanoparticles that are derived from intracellular dissociation of large nanoparticles. Biomaterials 2012, 33:4220-4228.
93. Duvvuri M., Krise J.P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front. Biosci. 2005, 10:1499-1509.
94. Misra R., Sahoo S.K. Coformulation of doxorubicin and curcumin in poly(d, l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol. Pharm. 2011, 8:852-866.
95. Brown S.D., Nativo P., Smith J.A., Stirling D., Edwards P.R., Venugopal B., Flint D.J., Plumb J.A., Graham D., Wheate N.J. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc. 2010, 132:4678-4684.
96. Dhar S., Daniel W.L., Giljohann D.A., Mirkin C.A., Lippard S.J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(iv) warheads. J. Am. Chem. Soc. 2009, 131:14652-14653.
97. Xu Y., Wang Q., He P., Dong Q., Liu F., Liu Y., Lin L., Yan H., Zhao X. Cell nucleus penetration by quantum dots induced by nuclear staining organic fluorophore and UV-irradiation. Adv. Mater. 2008, 20:3468-3473.
98. Zhou C., Long M., Qin Y., Sun X., Zheng J. Luminescent gold nanoparticles with efficient renal clearance. Angew. Chem. Int. Ed. Engl. 2011, 50:3168-3172.
99. Wong C., Stylianopoulos T., Cui J., Martin J., Chauhan V.P., Jiang W., Popovic Z., Jain R.K., Bawendi M.G., Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2426-2431.
100. Shen Y., Zhou Z., Sui M., Tang J., Xu P., Van Kirk E.A., Murdoch W.J., Fan M., Radosz M. Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery. Nanomedicine (Lond.) 2010, 5:1205-1217.
101. Ziady A.G., Gedeon C.R., Miller T., Quan W., Payne J.M., Hyatt S.L., Fink T.L., Muhammad O., Oette S., Kowalczyk T., Pasumarthy M.K., Moen R.C., Cooper M.J., Davis P.B. Transfection of airway epithelium by stable PEGylated poly-l-lysine DNA nanoparticles in vivo. Mol. Ther. 2003, 8:936-947.
102. Jin Y.H., Hu H.Y., Qiao M.X., Zhu J., Qi J.W., Hu C.J., Zhang Q., Chen D.W. pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation. Colloids Surf. B: Biointerfaces 2012, 94:184-191.
103. Wang Y., Jones E.M., Tang Y., Ji E., Lopez G.P., Chi E.Y., Schanze K.S., Whitten D.G. Effect of polymer chain length on membrane perturbation activity of cationic phenylene ethynylene oligomers and polymers. Langmuir 2011, 27:10770-10775.
104. Kadlecova Z., Baldi L., Hacker D., Wurm F.M., Klok H.A. Comparative study on the in vitro cytotoxicity of linear, dendritic, and hyperbranched polylysine analogues. Biomacromolecules 2012, 13:3127-3137.
105. Soliman M., Nasanit R., Abulateefeh S.R., Allen S., Davies M.C., Briggs S.S., Seymour L.W., Preece J.A., Grabowska A.M., Watson S.A., Alexander C. Multicomponent synthetic polymers with viral-mimetic chemistry for nucleic acid delivery. Mol. Pharm. 2012, 9:1-13.
106. Lee E.S., Gao Z., Kim D., Park K., Kwon I.C., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Control. Release 2008, 129:228-236.
107. Zheng C., Yao X., Qiu L. Novel polymeric vesicles with pH-induced deformation character for advanced drug delivery. Macromol. Biosci. 2011, 11:338-343.
108. El-Sayed M.E., Hoffman A.S., Stayton P.S. Rational design of composition and activity correlations for pH-responsive and glutathione-reactive polymer therapeutics. J. Control. Release 2005, 104:417-427.
109. Convertine A.J., Benoit D.S., Duvall C.L., Hoffman A.S., Stayton P.S. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J. Control. Release 2009, 133:221-229.
110. Lin Y.L., Jiang G., Birrell L.K., El-Sayed M.E. Degradable, pH-sensitive, membrane-destabilizing, comb-like polymers for intracellular delivery of nucleic acids. Biomaterials 2010, 31:7150-7166.
111. Henry S.M., El-Sayed M.E., Pirie C.M., Hoffman A.S., Stayton P.S. pH-responsive poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery. Biomacromolecules 2006, 7:2407-2414.
112. Yi C., Liu N., Zheng J., Jiang J., Liu X. Dual-responsive poly(styrene-alt-maleic acid)-graft-poly(n-isopropyl acrylamide) micelles as switchable emulsifiers. J. Colloid Interface Sci. 2012, 380:90-98.
113. Benoit D.S., Henry S.M., Shubin A.D., Hoffman A.S., Stayton P.S. pH-responsive polymeric siRNA carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol. Pharm. 2010, 7:442-455.
114. Shuhendler A.J., Cheung R.Y., Manias J., Connor A., Rauth A.M., Wu X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 2010, 119:255-269.
115. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 2006, 23:1574-1585.
116. Bochkov V.N., Oskolkova O.V., Birukov K.G., Levonen A.L., Binder C.J., Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid. Redox Signal. 2010, 12:1009-1059.
117. Pande A.H., Kar S., Tripathy R.K. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids. Biochim. Biophys. Acta 2010, 1798:442-452.
118. Wang Y., Chen L., Ding Y., Yan W. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro. Int. J. Pharm. 2012, 422:409-417.
119. Tang H., Guo J., Sun Y., Chang B., Ren Q., Yang W. Facile synthesis of pH sensitive polymer-coated mesoporous silica nanoparticles and their application in drug delivery. Int. J. Pharm. 2011, 421:388-396.
120. Pan Y.J., Chen Y.Y., Wang D.R., Wei C., Guo J., Lu D.R., Chu C.C., Wang C.C. Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release. Biomaterials 2012, 33:6570-6579.
121. Shalviri A., Chan H.K., Raval G., Abdekhodaie M.J., Liu Q., Heerklotz H., Wu X.Y. Design of pH-responsive nanoparticles of terpolymer of poly(methacrylic acid), polysorbate 80 and starch for delivery of doxorubicin. Colloids Surf. B: Biointerfaces 2013, 101:405-413.
122. Shalviri A., Raval G., Prasad P., Chan C., Liu Q., Heerklotz H., Rauth A.M., Wu X.Y. pH-dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. Eur. J. Pharm. Biopharm. 2012, 82:587-597.
123. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., Nel A.E. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
124. Li L., Guan Y., Liu H., Hao N., Liu T., Meng X., Fu C., Li Y., Qu Q., Zhang Y., Ji S., Chen L., Chen D., Tang F. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 2011, 5:7462-7470.
125. He Q., Gao Y., Zhang L., Zhang Z., Gao F., Ji X., Li Y., Shi J. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011, 32:7711-7720.
126. Liu X., Zhang J., Lynn D.M. Polyelectrolyte multilayers fabricated from 'charge-shifting' anionic polymers: a new approach to controlled film disruption and the release of cationic agents from surfaces. Soft Matter 2008, 4:1688-1695.
127. Guo S., Huang Y., Jiang Q., Sun Y., Deng L., Liang Z., Du Q., Xing J., Zhao Y., Wang P.C., Dong A., Liang X.J. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano 2010, 4:5505-5511.
128. Han L., Zhao J., Zhang X., Cao W., Hu X., Zou G., Duan X., Liang X.J. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface charge-reversal polymer assembly and good biocompatibility. ACS Nano 2012, 6:7340-7351.
129. Lee S.J., Min K.H., Lee H.J., Koo A.N., Rim H.P., Jeon B.J., Jeong S.Y., Heo J.S., Lee S.C. Ketal cross-linked poly(ethylene glycol)-poly(amino acid)s copolymer micelles for efficient intracellular delivery of doxorubicin. Biomacromolecules 2011, 12:1224-1233.
130. Qiao Z.Y., Zhang R., Du F.S., Liang D.H., Li Z.C. Multi-responsive nanogels containing motifs of ortho ester, oligo(ethylene glycol) and disulfide linkage as carriers of hydrophobic anti-cancer drugs. J. Control. Release 2011, 152:57-66.
131. Tang R., Ji W., Wang C. Amphiphilic block copolymers bearing ortho ester side-chains: pH-dependent hydrolysis and self-assembly in water. Macromol. Biosci. 2010, 10:192-201.
132. Meng L., Zhang X., Lu Q., Fei Z., Dyson P.J. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials 2012, 33:1689-1698.
133. Broxterman H.J., Gotink K.J., Verheul H.M.W. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Updat. 2009, 12:114-126.
134. Kievit F.M., Wang F.Y., Fang C., Mok H., Wang K., Silber J.R., Ellenbogen R.G., Zhang M. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control. Release 2011, 152:76-83.
135. Wang F., Wang Y.C., Dou S., Xiong M.H., Sun T.M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
136. Savla R., Taratula O., Garbuzenko O., Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Release 2011, 153:16-22.
137. Kiziltepe T., Ashley J.D., Stefanick J.F., Qi Y.M., Alves N.J., Handlogten M.W., Suckow M.A., Navari R.M., Bilgicer B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012, 2:e64.
138. Lee C.H., Cheng S.H., Huang I.P., Souris J.S., Yang C.S., Mou C.Y., Lo L.W. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew. Chem. Int. Ed. Engl. 2010, 49:8214-8219.
139. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 2011, 133:17560-17563.
140. Li Y.-L., Zhu L., Liu Z., Cheng R., Meng F., Cui J.-H., Ji S.-J., Zhong Z. Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells. Angew. Chem. Int. Ed. Engl. 2009, 48:9914-9918.
141. Manickam D.S., Hirata A., Putt D.A., Lash L.H., Hirata F., Oupicky D. Overexpression of Bcl-2 as a proxy redox stimulus to enhance activity of non-viral redox-responsive delivery vectors. Biomaterials 2008, 29:2680-2688.
142. Van Laer K., Hamilton C.J., Messens J. Low molecular weight thiols in thiol disulfide exchange. Antioxid. Redox Signal. 2012, 10.1089/ars.2012.4964.
143. Tang L.Y., Wang Y.C., Li Y., Du J.Z., Wang J. Shell-detachable micelles based on disulfide-linked block copolymer as potential carrier for intracellular drug delivery. Bioconjug. Chem. 2009, 20:1095-1099.
144. Meng F., Hennink W.E., Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 2009, 30:2180-2198.
145. Nam H.Y., Nam K., Lee M., Kim S.W., Bull D.A. Dendrimer type bio-reducible polymer for efficient gene delivery. J. Control. Release 2012, 160:592-600.
146. Sheng R., Luo T., Zhu Y., Li H., Sun J., Chen S., Sun W., Cao A. The intracellular plasmid DNA localization of cationic reducible cholesterol-disulfide lipids. Biomaterials 2011, 32:3507-3519.
147. Guo Q., Luo P., Luo Y., Du F., Lu W., Liu S., Huang J., Yu J. Fabrication of biodegradable micelles with sheddable poly(ethylene glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin. Colloids Surf. B: Biointerfaces 2012, 100:138-145.
148. Thambi T., Yoon H.Y., Kim K., Kwon I.C., Yoo C.K., Park J.H. Bioreducible block copolymers based on poly(ethylene glycol) and poly(gamma-benzyl l-glutamate) for intracellular delivery of camptothecin. Bioconjug. Chem. 2011, 22:1924-1931.
149. Galmarini C.M., Warren G., Senanayake M.T., Vinogradov S.V. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. Int. J. Pharm. 2010, 395:281-289.
150. Wang Y.C., Wang F., Sun T.M., Wang J. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells. Bioconjug. Chem. 2011, 22:1939-1945.
151. Yu Z.Q., Yan J.J., You Y.Z., Zhou Q.H. Bioreducible and acid-labile poly(amido amine)s for efficient gene delivery. Int. J. Nanomedicine 2012, 7:5819-5832.
152. Won Y.W., Yoon S.M., Lee K.M., Kim Y.H. Poly(oligo-d-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. Mol. Ther. 2011, 19:372-380.
153. Gao Y., Chen L., Zhang Z., Chen Y., Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 2011, 32:1738-1747.
154. Yin Q., Shen J., Chen L., Zhang Z., Gu W., Li Y. Overcoming multidrug resistance by co-delivery of mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012, 33:6495-6506.
155. Salm F., Cwiek P., Ghosal A., Lucia Buccarello A., Largey F., Wotzkow C., Höland K., Styp-Rekowska B., Djonov V., Zlobec I., Bodmer N., Gross N., Westermann F., Schäfer S., Arcaro A. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene 2012, 10.1038/onc.2012.416.
156. Circu M.L., Aw T.Y. Glutathione and modulation of cell apoptosis. Biochim. Biophys. Acta 2012, 1823:1767-1777.
157. Gu Y.J., Cheng J., Man C.W., Wong W.T., Cheng S.H. Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine 2012, 8:204-211.
158. Wellhoner H., Weiss A., Schulz A., Adermann K., Braitbard O., Bar-Sinai A., Hochman J. Reversing ABCB1-mediated multi-drug resistance from within cells using translocating immune conjugates. J. Drug Target. 2012, 20:445-452.
159. Dubikovskaya E.A., Thorne S.H., Pillow T.H., Contag C.H., Wender P.A. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12128-12133.
160. Anand S., Ortel B.J., Pereira S.P., Hasan T., Maytin E.V. Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett. 2012, 326:8-16.
161. Kepczynski M., Dzieciuch M., Nowakowska M. Nanostructural hybrid sensitizers for photodynamic therapy. Curr. Pharm. Des. 2012, 18:2607-2621.
162. Milgrom L.R. Towards recombinant antibody-fragment targeted photodynamic therapy. Sci. Prog. 2008, 91:241-263.
163. Schmitt F., Juillerat-Jeanneret L. Drug targeting strategies for photodynamic therapy. Anti Cancer Agents Med. Chem. 2012, 12:500-525.
164. Tang Y., Borgstrom P., Maynard J., Koziol J., Hu Z., Garen A., Deisseroth A. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther. 2007, 14:346-353.
165. Duanmu J., Cheng J., Xu J., Booth C.J., Hu Z. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. Br. J. Cancer 2011, 104:1401-1409.
166. Novichenko N.L., Mamchur A.A., Lisniak I.O., Gamaliya M.F. Study of photodynamic efficiency of the hematoporphyrin conjugated with antibody to VEGF in mouse Lewis carcinoma. Exp. Oncol. 2008, 30:315-318.
167. Tacelosky D.M., Creecy A.E., Shanmugavelandy S.S., Smith J.P., Claxton D.F., Adair J.H., Kester M., Barth B.M. Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. Discov. Med. 2012, 13:275-285.
168. Barth B.M., Altinoǧlu E.I., Shanmugavelandy S.S., Kaiser J.M., Crespo-Gonzalez D., DiVittore N.A., McGovern C., Goff T.M., Keasey N.R., Adair J.H., Loughran T.P., Claxton D.F., Kester M. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 2011, 5:5325-5337.
169. Peng C.L., Lai P.S., Lin F.H., Wu S.Y.H., Shieh M.J. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using sn-38-loaded chlorin-core star block copolymer micelles. Biomaterials 2009, 30:3614-3625.
170. Lu H.L., Syu W.J., Nishiyama N., Kataoka K., Lai P.S. Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo. J. Control. Release 2011, 155:458-464.
171. Shieh M.J., Hsu C.Y., Huang L.Y., Chen H.Y., Huang F.H., Lai P.S. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J. Control. Release 2011, 152:418-425.
172. Khdair A., Handa H., Mao G., Panyam J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur. J. Pharm. Biopharm. 2009, 71:214-222.
173. Tang Y., Lei T., Manchanda R., Nagesetti A., Fernandez-Fernandez A., Srinivasan S., McGoron A.J. Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm. Res. 2010, 27:2242-2253.
174. Goodrich G.P., Bao L., Gill-Sharp K., Sang K.L., Wang J., Payne J.D. Photothermal therapy in a murine colon cancer model using near-infrared absorbing gold nanorods. J. Biomed. Opt. 2010, 15:018001.
175. Tan A., Yildirimer L., Rajadas J., De La Peña H., Pastorin G., Seifalian A. Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine. Nanomedicine (Lond.) 2011, 6:1101-1114.
176. Li R., Wu R., Zhao L., Wu M., Yang L., Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 2010, 4:1399-1408.
177. Lukianova-Hleb E.Y., Wagner D.S., Brenner M.K., Lapotko D.O. Cell-specific transmembrane injection of molecular cargo with gold nanoparticle-generated transient plasmonic nanobubbles. Biomaterials 2012, 33:5441-5450.
178. Lukianova-Hleb E.Y., Belyanin A., Kashinath S., Wu X., Lapotko D.O. Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells. Biomaterials 2012, 33:1821-1826.
179. Lukianova-Hleb E.Y., Ren X., Townley D., Wu X., Kupferman M.E., Lapotko D.O. Plasmonic nanobubbles rapidly detect and destroy drug-resistant tumors. Theranostics 2012, 2:976-987.
180. Lukianova-Hleb E.Y., Ren X., Zasadzinski J.A., Wu X., Lapotko D.O. Plasmonic nanobubbles enhance efficacy and selectivity of chemotherapy against drug-resistant cancer cells. Adv. Mater. 2012, 24:3831-3837.
181. Caldorera-Moore M.E., Liechty W.B., Peppas N.A. Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc. Chem. Res. 2011, 44:1061-1070.
182. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
183. Hua M.Y., Yang H.W., Chuang C.K., Tsai R.Y., Chen W.J., Chuang K.L., Chang Y.H., Chuang H.C., Pang S.T. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010, 31:7355-7363.
184. Chomoucka J., Drbohlavova J., Huska D., Adam V., Kizek R., Hubalek J. Magnetic nanoparticles and targeted drug delivering. Pharmacol. Res. 2010, 62:144-149.
185. Sillerud L.O., Solberg N.O., Chamberlain R., Orlando R.A., Heidrich J.E., Brown D.C., Brady C.I., Vander Jagt T.A., Garwood M., Vander Jagt D.L. Spion-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain. J. Alzheimers Dis. 2012, 10.3233/JAD-121171.
186. Hosseini F., Panahifar A., Adeli M., Amiri H., Lascialfari A., Orsini F., Doschak M.R., Mahmoudi M. Synthesis of pseudopolyrotaxanes-coated superparamagnetic iron oxide nanoparticles as new MRI contrast agent. Colloids Surf. B: Biointerfaces 2012, 10.1016/j.colsurfb.2012.10.035.
187. Singh A., Dilnawaz F., Sahoo S.K. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One 2011, 6:e26803.
188. Kim J.H., Song M., Kang G.H., Lee E.R., Choi H.Y., Lee C., Kim J.H., Kim Y., Koo B.N., Cho S.G. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells. Leuk. Res. 2012, 36:1157-1164.
189. 4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int. J. Nanomedicine 2009, 4:107-114.
190. El-Dakdouki M.H., Zhu D.C., El-Boubbou K., Kamat M., Chen J., Li W., Huang X. Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. Biomacromolecules 2012, 13:1144-1151.
191. 4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int. J. Nanomedicine 2009, 4:73-78.
192. Krishnan S., Diagaradjane P., Cho S.H. Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int. J. Hyperthermia 2010, 26:775-789.
193. Li J., Qu Y., Ren J., Yuan W., Shi D. Magnetocaloric effect in magnetothermally-responsive nanocarriers for hyperthermia-triggered drug release. Nanotechnology 2012, 23:505706.
194. Lee J.H., Jang J.T., Choi J.S., Moon S.H., Noh S.H., Kim J.W., Kim J.G., Kim I.S., Park K.I., Cheon J. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat. Nanotechnol. 2011, 6:418-422.
195. Noh S.H., Na W., Jang J.T., Lee J.H., Lee E.J., Moon S.H., Lim Y., Shin J.S., Cheon J. Nanoscale magnetism control via surface and exchange anisotropy for optimized ferrimagnetic hysteresis. Nano Lett. 2012, 12:3716-3721.
196. 4 nanoparticles with daunorubicin induce apoptosis through caspase 8-parp pathway and inhibit K562 leukemia cell-induced tumor growth in vivo. Nanomedicine 2011, 7:595-603.
197. 4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int. J. Nanomedicine 2012, 7:2261-2269.
198. Schroeder A., Kost J., Barenholz Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem. Phys. Lipids 2009, 162:1-16.
199. Miller D.L., Smith N.B., Bailey M.R., Czarnota G.J., Hynynen K., Makin I.R.S., B.C.o.t.A.I.o.U.i.Medicine Overview of therapeutic ultrasound applications and safety considerations. J. Ultrasound Med. 2012, 31:623-634.
200. Li P., Zheng Y., Ran H., Tan J., Lin Y., Zhang Q., Ren J., Wang Z. Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice. J. Control. Release 2012, 162:349-354.
201. Castle J., Butts M., Healey A., Kent K., Marino M., Feinstein S.B. Ultrasound mediated targeted drug delivery: recent success and remaining challenges. Am. J. Physiol. Heart Circ. Physiol. 2012, 10.1152/ajpheart.00265.2012.
202. Siu T., Rohling R., Chiao M. Microdevice-based delivery of gene products using sonoporation. Biomed. Microdevices 2007, 9:295-300.
203. Jackson J.K., Pirmoradi F.N., Wan C.P., Siu T., Chiao M., Burt H.M. Increased accumulation of paclitaxel and doxorubicin in proliferating capillary cells and prostate cancer cells following ultrasound exposure. Ultrasonics 2011, 51:932-939.
204. Wan C.P., Jackson J.K., Pirmoradi F.N., Chiao M., Burt H.M. Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure. Ultrasound Med. Biol. 2012, 38:736-744.
205. Sanches P.G., Grull H., Steinbach O.C. See, reach, treat: ultrasound-triggered image-guided drug delivery. Ther. Deliv. 2011, 2:919-934.
206. Delalande A., Postema M., Mignet N., Midoux P., Pichon C. Ultrasound and microbubble-assisted gene delivery: recent advances and ongoing challenges. Ther. Deliv. 2012, 3:1199-1215.
207. Guo Z., Hong S., Jin X., Luo Q., Wang Z., Wang Y. Study on the multidrug resistance 1 gene transfection efficiency using adenovirus vector enhanced by ultrasonic microbubbles in vitro. Mol. Biotechnol. 2011, 48:138-146.
208. Pan Y., He B., Song G., Bao Q., Tang Z., Tian F., Wang S. Cd147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Oncol. Rep. 2012, 27:2003-2009.
209. Yamada R., Kostova M.B., Anchoori R.K., Xu S., Neamati N., Khan S.R. Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biol. Ther. 2010, 9:192-203.
210. Jiang Q., Song C., Nangreave J., Liu X., Lin L., Qiu D., Wang Z.G., Zou G., Liang X., Yan H., Ding B. DNA origami as a carrier for circumvention of drug resistance. J. Am. Chem. Soc. 2012, 134:13396-13403.
211. Li Y., Zeng Y., Mooney S.M., Yin B., Mizokami A., Namiki M., Getzenberg R.H. Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. J. Cell. Biochem. 2011, 112:2125-2137.
212. Gasselhuber A., Dreher M.R., Rattay F., Wood B.J., Haemmerich D. Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. PLoS One 2012, 7:e47453.
213. Gaber M.H. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J. Biochem. Mol. Biol. Biophys. 2002, 6:309-314.
214. Bidwell G.L., Davis A.N., Fokt I., Priebe W., Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest. New Drugs 2007, 25:313-326.
215. Bidwell G.L., Perkins E., Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett. 2012, 319:136-143.
216. He C., Zhuang X., Tang Z., Tian H., Chen X. Stimuli-sensitive synthetic polypeptide-based materials for drug and gene delivery. Adv. Healthc. Mater. 2012, 1:48-78.
217. Chen X., Gambhir S.S., Cheon J. Theranostic nanomedicine. Acc. Chem. Res. 2011, 44:841.
218. 4 microspheres for magnetic-targeted and pH-triggered anticancer drug delivery. Chemistry 2012, 18:15676-15682.
219. Kievit F.M., Veiseh O., Fang C., Bhattarai N., Lee D., Ellenbogen R.G., Zhang M. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010, 4:4587-4594.
220. Kievit F.M., Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res. 2011, 44:853-862.
221. Fang C., Kievit F.M., Veiseh O., Stephen Z.R., Wang T., Lee D., Ellenbogen R.G., Zhang M. Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. J. Control. Release 2012, 162:233-241.
222. Moktan S., Ryppa C., Kratz F., Raucher D. A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. Invest. New Drugs 2012, 30:236-248.
223. Jiang X.L., Li L.H., Liu J., Hennink W.E., Zhuo R.X. Facile fabrication of thermo-responsive and reduction-sensitive polymeric micelles for anticancer drug delivery. Macromol. Biosci. 2012, 12:703-711.
224. Tang H.D., Murphy C.J., Zhang B., Shen Y.Q., Sui M.H., Van Kirk E.A., Feng X.W., Murdoch W.J. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine (Lond.) 2010, 5:855-865.
225. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., Kamat A.A., Spannuth W.A., Gershenson D.M., Lutgendorf S.K., Aggarwal B.B., Sood A.K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin. Cancer Res. 2007, 13:3423-3430.
226. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.
227. Wadhwa S., Mumper R.J. Polypeptide conjugates of d-penicillamine and idarubicin for anticancer therapy. J. Control. Release 2012, 158:215-223.
228. Wen X., Jackson E.F., Price R.E., Kim E.E., Wu Q., Wallace S., Charnsangavej C., Gelovani J.G., Li C. Synthesis and characterization of poly(l-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjug. Chem. 2004, 15:1408-1415.
229. Chang H.I., Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 2012, 7:49-60.
230. Hauck M.L., LaRue S.M., Petros W.P., Poulson J.M., Yu D., Spasojevic I., Pruitt A.F., Klein A., Case B., Thrall D.E., Needham D., Dewhirst M.W. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin. Cancer Res. 2006, 12:4004-4010.
231. ClinicalTrials.gov (homepage on the Internet) Phase 3 study of ThermoDox with Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) Available from:. http://www.clinicaltrials.gov/ct2/show/NCT00617981.
232. Celsion Coporation Clinical trials Available from:. http://www/celsion.com/trials.cfminternet.